Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan

被引：0
|
作者：
Bae, Jung-Woo
Han, Ho-Kyun
Lee, Hwan-Joo
Jung, Dong -Won
Kim, Nam-Tae
Lee, Jin-Hee
Jang, Choon-Gon
Choi, Sun-Ok
Kim, Ok-Hee
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [1] Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
    Jung-woo Bae
    Chang-ik Choi
    Mi-jeong Kim
    Da-hee Oh
    Seul-ki Keum
    Jung-in Park
    Bo-hye Kim
    Hye-kyoung Bang
    Sung-gon Oh
    Byung-sung Kang
    Hyun-joo Park
    Hae-deun Kim
    Ji-hey Ha
    Hee-jung Shin
    Young-hoon Kim
    Han-sung Na
    Myeon-woo Chung
    Choon-gon Jang
    Seok-yong Lee
    Acta Pharmacologica Sinica, 2011, 32 : 1303 - 1308
  • [2] Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
    Bae, Jung-woo
    Choi, Chang-ik
    Kim, Mi-jeong
    Oh, Da-hee
    Keum, Seul-ki
    Park, Jung-in
    Kim, Bo-hye
    Bang, Hye-kyoung
    Oh, Sung-gon
    Kang, Byung-sung
    Lee, Hye-in
    Lee, Yun-jeong
    Park, Hyun-joo
    Kim, Hae-deun
    Ha, Ji-hey
    Shin, Hee-jung
    Kim, Young-hoon
    Na, Han-sung
    Chung, Myeon-woo
    Han, Soon-young
    Kim, Seung-hee
    Jang, Choon-gon
    Lee, Seok-yong
    ACTA PHARMACOLOGICA SINICA, 2011, 32 (10) : 1303 - 1308
  • [3] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics.
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 213 - 213
  • [4] Role of CYP2C9 polymorphism in losartan oxidation
    Yasar, Ü
    Tybring, G
    Hidestrand, M
    Oscarson, M
    Ingelman-Sundberg, M
    Dahl, ML
    Eliasson, E
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (07) : 1051 - 1056
  • [5] Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects
    Huang, Hang-Xing
    Wu, He
    Zhao, Yingying
    Zhou, Tao
    Ai, Xin
    Dong, Yu
    Zhang, Yan
    Lai, Yong
    XENOBIOTICA, 2021, 51 (05) : 616 - 623
  • [6] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04): : 418 - 424
  • [7] The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
    Kobayashi, Mariko
    Takagi, Miho
    Fukumoto, Kyoko
    Kato, Ryuji
    Tanaka, Kazuhiko
    Ueno, Kazuyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 115 - 119
  • [8] Polymorphisms of MDR1 and CYP2C9 genes in the Czech population.
    Buzková, Helena
    Pechandová, Kristina
    Mikoviny, Rudolf
    Slanar, Ondrej
    Perlík, Frantisek
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 232 - 232
  • [9] Effects of CYP2C9 genetic polymorphism on the pharmacokinetics of zafirlukast.
    Kim, Mi-Jung
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E234 - E234
  • [10] Influence Of The Polymorphism In CYP2C9, CYP2C19 And MDR1 On Risk Of Development Of Side Effects Due To Valproic Acide In Patients With Epilepsy
    Sergeeva, T.
    Glotov, A.
    Danilova, M.
    Odintsova, G.
    Koroleva, N.
    EPILEPSIA, 2019, 60 : 174 - 174
12345